My CML provides patients with Chronic Myeloid Leukaemia (CML) with a multi-purpose and user-friendly resource that aims to empower patients and their families/ carers to optimally manage their condition.

Designed by a team of NHS Pharmacists working closely with key CML patient support groups, My CML contains a set of specially designed functions to promote optimal patient outcomes. These include:

- A symptom/side effect tracker. Patients can record how they are feeling on a particular day, either in the form of a diary entry or by recording a score (on a scale of 0-10) for particular symptoms e.g. nausea, diarrhoea, muscle cramps etc.

- A drug interaction checker. Patients or their family member/ carer can check if there are any interactions between their CML medication and other medications. The app uses a traffic light system to tell the user whether there is likely to be an interaction between any two medications and how significant any interaction is likely to be.

- A medication reminder tool. Patients or their family member/ carer can set a daily reminder to help them remember to take the CML medication (and any other medication that they might take regularly). Patients can also record every time they take a dose of their medication to check how good their adherence is using the My Progress function, and generate a graph to share with their healthcare provider.

- The ability to enter key lab test results. Patients or their family member/ carer can record important blood test results such as BCR-ABL PCR, full blood count, kidney function and liver function. Patients can then keep track of their results over time using the tables and graphs in the My Progress section.

- An appointment diary. Patients or their family member/ carer can keep track of all CML-related appointments. It also has a notes function so that patients can record any questions or topics that they might want to talk about to their health care provider.

- Access to up to date CML information including guidelines, information on medicines and various support groups both for CML and for cancers in general.

My CML is designed to help patients achieve improved adherence to treatment, which is particularly important in CML where there is strong evidence that poor adherence can lead to significantly worse clinical outcomes than when high levels of adherence are achieved.